Additional file 1 of The impact of the COVID-19 pandemic on cardiovascular disease prevention and corresponding geographical inequalities in England: interrupted time series analysis
Creators: name: Castanon, Alejandra
name: Grasic, Katja
name: Chen, Simon
name: Ma, Florence
name: Oboli, Godspower
name: Bray, Benjamin D.
name: Hughes, Andrew
name: White, Martin
name: Ahmad, Shahed
name: Pearson-Stuttard, Jonathan
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Environmental Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Cancer
subject: Computational Biology

description: Additional file 1: Supplemental methods. Table S1. List of paragraphs from BNF chapter 2 according to clinical indication. Table S2. Summary of data sources, calendar years and population used by analysis and disease. Table S3. Sub-ICB age standardised hypertension prevalence. Top 10 Sub-ICBs with the highest and lowest prevalence. Table S4. Sub-ICB age standardised atrial fibrillation prevalence. Top 10 Sub-ICBs with the highest and lowest prevalence. Table S5. LSOAs age standardised hypertension prevalence. Top 10 LSOAs with the highest and lowest prevalence. Table S6. LSOAs age standardised atrial fibrillation prevalence. Top 10 LSOAs with the highest and lowest prevalence. Table S7. Results of the overall ITS analysis on the Sub-IBC level. Table S8. Missed diagnoses of hypertension and impact on cardiovascular disease by Region. Table S9. Sub-ICBs hypertension treatment achievement rates. Top 10 sub-ICBs with the highest and lowest achievement rates. Table S10.  Hypertension treatment achievement rate (2021-22) by Region. Table S11. LSOAs hypertension treatment achievement rates. Top 10 LSOAs with the highest and lowest achievement rate. Table S12. LSOAs Atrial Fibrillation risk assessment treatment achievement rate. Top 10 LSOAs with the highest and lowest achievement rates. Table S13. CCGs percent difference in monthly prescription rates of oral anticoagulants medication between March 2020 – April 2022. Top 10 CCGs with the highest and lowest percentage difference. Table S14. CCGs percent difference in monthly prescription rates of hypertension and heart failure medication between March 2020 – April 2022. Top 10 CCGs with the highest and lowest percentage difference. Figure S1. Observed and predicted prevalence of hypertension pre and post COVID-19 in England. Figure S2. Observed and predicted prevalence of atrial fibrillation pre and post COVID-19 in England. Figure S3. Age standardised prevalence rates of A) Hypertension Figure S3. Missed diagnoses of atrial fibrillation between April 2020 and March 2021. Figure S4. Treatment achievement rates in 2019/20 and 2021/22 at sub-ICB level in England for A) Hypertension, B) individuals with a CHA2DS2-VASc score of 2 or more treated with anti-coagulation therapy and C) AF risk assessment. Figure S5. Prescription rate (items per 1,000 person days) for medications for A) Heart failure, B) Hypertension, C) both Hypertension and Heart Failure and D) Oral anticoagulants pre and post COVID-19. Figure S6. Age standardised prevalence of Atrial fibrillation and hypertension by index of deprivation decile. Figure S7. Missed diagnoses of A) Hypertension and B) Atrial fibrillation by index of deprivation decile. Treatment achievement rates of A) Hypertension and B) Anti-coagulation and C)risk assessment by index of deprivation decile.